glp 1 analog GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development GLP-1 receptor agonists for individualized

Standards of Care in Diabetes2025

Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system

It is not approved for any of these yet, but the intent is clearly broader metabolic health, not just weight loss

Each plan is created and monitored by your licensed provider to support your goals safely and thoughtfully

Furthermore, post hoc subgroup analyses of cardiovascular outcome trials have suggested a greater cardiorenal protection in patients treated with a combination versus either monotherapy